What is the NAFLD Fibrosis Score (NFS)?

The NAFLD Fibrosis Score (NFS), also called the NAFLD fibrosis index, is a validated non-invasive blood test formula that estimates the likelihood of advanced liver fibrosis (bridging fibrosis F3 or cirrhosis F4) in patients with non-alcoholic fatty liver disease (NAFLD), now often termed MASLD. It combines age, BMI, diabetes/IFG status, AST/ALT ratio, platelet count, and albumin—variables available on routine labs without liver biopsy.

How is the NAFLD Fibrosis Score calculated?

NFS = −1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × diabetes/IFG (1 if yes, 0 if no) + 0.99 × (AST/ALT ratio) − 0.013 × platelet count (×10⁹/L) − 0.66 × albumin (g/dL). Published by Angulo et al. in Hepatology (2007). Example: age 55, BMI 32, no diabetes, AST 50, ALT 40, platelets 200, albumin 4.0 → AST/ALT 1.25 → NFS ≈ −0.63 (indeterminate zone).

What NFS cutoffs indicate advanced fibrosis?

Per the original validation cohort: NFS 0.676 rules in advanced fibrosis (positive predictive value ~90%); scores between −1.455 and 0.676 are indeterminate (~32% of patients) and require further testing such as FibroScan or specialist assessment.

What does a low NFS mean?

A low NFS (below −1.455) suggests advanced fibrosis is unlikely. Most patients in this range have no or mild fibrosis (F0–F2). Continue lifestyle management—7–10% weight loss, Mediterranean diet, exercise—and routine liver enzyme monitoring. A low NFS does not guarantee a healthy liver if steatosis or inflammation persists.

What does an indeterminate NFS mean?

An indeterminate NFS (−1.455 to 0.676) cannot reliably exclude or confirm advanced fibrosis. Do not assume mild disease. Request transient elastography (FibroScan), MRI-PDFF, or hepatology referral. About one-third of NAFLD patients fall in this zone—additional non-invasive tests improve staging accuracy.

What does a high NFS mean?

A high NFS (above 0.676) indicates a high probability of bridging fibrosis (F3) or cirrhosis (F4). Prompt hepatology evaluation is recommended. Assess for portal hypertension, varices, and hepatocellular carcinoma surveillance if cirrhosis is confirmed. High NFS is a screening result—not a biopsy replacement.

What labs do I need for the NFS calculator?

You need: age, BMI (or height and weight), diabetes or impaired fasting glucose status, AST and ALT from liver function tests, platelet count from CBC, and serum albumin. All are standard outpatient labs. Fasting is not required for NFS itself, though glucose testing may need fasting per lab protocol.

What units should I use for platelets and albumin?

Platelets: enter as ×10⁹/L or ×10³/µL (same numeric value, e.g., 220). Albumin: enter as g/dL (US standard) or g/L (divide by 10 for g/dL). AST and ALT are in U/L. BMI is kg/m². This calculator converts albumin to g/dL automatically for the formula.

Why does diabetes increase the NFS?

Type 2 diabetes and impaired fasting glucose (IFG) add 1.13 points to NFS because insulin resistance accelerates fibrosis progression in NAFLD/MASH. Up to 70% of type 2 diabetics have fatty liver disease. Optimizing HbA1c and weight reduces fibrosis risk over time.

What is the significance of AST/ALT ratio in NFS?

AST/ALT ratio ≥ 1.0 often suggests fibrosis-related mitochondrial injury rather than pure steatosis, where ALT typically exceeds AST. The NFS formula adds 0.99 × (AST/ALT) points—higher ratios raise the score. Alcohol, muscle injury, and medications can also elevate AST independently.

How accurate is the NAFLD Fibrosis Score?

In the derivation cohort, NFS 0.676 had ~67% sensitivity and ~97% specificity. Meta-analyses confirm NFS is among the best simple blood-based fibrosis scores for NAFLD, though indeterminate results are common and elastography improves accuracy.

How is NFS different from FIB-4?

Both are non-invasive fibrosis scores using routine labs. FIB-4 = (age × AST) / (platelets × √ALT) and uses age, AST, ALT, and platelets only—no BMI, albumin, or diabetes. NFS includes metabolic variables and is specifically validated for NAFLD. Discordant results warrant specialist review and FibroScan.

How is NFS different from the Fatty Liver Risk Calculator?

Our Fatty Liver Risk Calculator screens lifestyle and metabolic risk for developing NAFLD/MASLD—it does not stage fibrosis. The NFS Calculator uses blood tests to estimate advanced fibrosis probability in patients who already have fatty liver disease. Use both: risk screening first, NFS when you have lab results.

Can NFS be used in alcoholic liver disease?

No. NFS was validated specifically in non-alcoholic fatty liver disease without significant alcohol intake. Heavy alcohol use causes alcoholic liver disease (AFLD) and invalidates NFS interpretation. If you drink >14 units/week, discuss AFLD and NAFLD overlap with your doctor.

Does NFS work in lean NAFLD?

NFS can be used in lean NAFLD (normal BMI with hepatic steatosis), though BMI contributes less. Lean patients may have discordant NFS and imaging—indeterminate scores are especially important to follow with FibroScan. Metabolic factors (insulin resistance, waist circumference) still drive fibrosis risk.

When should I see a hepatologist?

See a hepatologist if NFS > 0.676 (high probability of advanced fibrosis), NFS is indeterminate with persistent ALT elevation, you have diabetes plus obesity plus elevated liver enzymes, or symptoms like jaundice, ascites, or unexplained weight loss. NFS < −1.455 with normal enzymes may be managed by primary care with lifestyle focus.

What is FibroScan and when do I need it?

FibroScan (transient elastography) measures liver stiffness in kPa to estimate fibrosis stage non-invasively. It is recommended when NFS is indeterminate or high, or when treatment decisions depend on fibrosis stage. Cost in India: roughly ₹3,000–8,000. It does not replace NFS but complements it.

Can weight loss improve my NFS?

Yes. Sustained 7–10% body weight loss reduces liver fat, inflammation, and fibrosis progression—often lowering AST, improving AST/ALT ratio, and shifting NFS toward lower values over 6–12 months. Recheck NFS after meaningful lifestyle change. Advanced cirrhosis requires specialist care beyond diet alone.

What medications treat MASH with fibrosis?

Resmetirom (Rezdiffra) is FDA-approved for MASH with F2–F3 fibrosis. GLP-1 agonists (semaglutide, tirzepatide) show fibrosis benefits in trials. Pioglitazone and vitamin E have evidence in selected patients. All require hepatology guidance—never self-prescribe based on NFS alone.

Does this calculator diagnose cirrhosis?

No. This tool provides an educational NFS estimate using the Angulo formula and published cutoffs. Diagnosis of cirrhosis requires clinical evaluation, imaging, elastography, and sometimes liver biopsy. If you have jaundice, vomiting blood, severe abdominal swelling, or confusion, seek emergency care immediately.

What NFS result is normal?

There is no 'normal' NFS like a cholesterol target. NFS 0.676 is unfavorable. Healthy adults without NAFLD are not typically screened with NFS—the test is for patients with known or suspected fatty liver disease.

How often should I recheck NFS?

After lifestyle intervention, recheck in 6–12 months if metabolic risk persists. Annually is reasonable for stable NAFLD with low NFS. Indeterminate or high NFS warrants sooner specialist follow-up and elastography rather than serial NFS alone. Always align timing with your hepatologist.

Can platelets be low in NAFLD without cirrhosis?

Yes, though thrombocytopenia (<150 ×10⁹/L) often signals portal hypertension in advanced fibrosis. Low platelets mathematically lower NFS (protective in the formula) but may themselves indicate serious liver disease—interpret the full clinical picture, not NFS in isolation.

What is MASLD vs NAFLD?

MASLD (metabolic dysfunction-associated steatotic liver disease) is the 2023 renaming of NAFLD, emphasizing metabolic drivers over alcohol exclusion. NFS validation predates the name change but applies to the same patient population—hepatic steatosis with cardiometabolic risk factors and minimal alcohol.

Is NFS validated for the Indian population?

NFS was derived in a multinational cohort including diverse ethnicities. South Asians develop NAFLD at lower BMI (≥23 kg/m² overweight per WHO Asia-Pacific). NFS remains clinically used in India, though local validation studies suggest similar cutoffs perform reasonably—always pair with clinical context and imaging when indeterminate.

What is a normal AST/ALT ratio in NAFLD?

In simple steatosis, ALT typically exceeds AST and the ratio is below 1.0. As fibrosis advances, mitochondrial injury raises AST disproportionately and the AST/ALT ratio rises to ≥1.0—a key NFS driver (0.99 × ratio added to score). Ratio above 1.0 alone does not diagnose cirrhosis but warrants further staging.

How much does each NFS variable change the score?

Per unit: age +0.037/year, BMI +0.094/kg/m², diabetes/IFG +1.13 (fixed), AST/ALT ratio +0.99 per ratio point, platelets −0.013 per ×10⁹/L, albumin −0.66 per g/dL. Example: dropping albumin from 4.0 to 3.5 g/dL adds ~0.33 NFS points; adding diabetes adds 1.13 points instantly.

What FibroScan result confirms advanced fibrosis?

Transient elastography ≥9.5 kPa suggests advanced fibrosis (F3); ≥12.5 kPa suggests cirrhosis (F4). Use FibroScan when NFS is indeterminate (−1.455 to 0.676) or high (>0.676). Cost in India: roughly ₹3,000–8,000. FibroScan does not replace NFS but complements it for staging decisions.

Can exercise alone improve NFS without weight loss?

Aerobic exercise (150+ min/week) reduces hepatic steatosis and can normalise liver enzymes even with modest weight change—potentially lowering AST/ALT ratio and NFS over months. However, 7–10% body weight loss remains the most proven intervention for fibrosis regression. Combine diet, exercise, and glycemic control for best results.

Should I use NFS or the Fatty Liver Risk Calculator first?

Use the Fatty Liver Risk Calculator first if you have not been diagnosed with fatty liver—it screens lifestyle and metabolic risk for developing NAFLD/MASLD. Use this NFS Calculator once you have fatty liver confirmed (ultrasound/MRI) and blood test results (AST, ALT, platelets, albumin) to stage fibrosis risk.

What happens if my NFS is high but I feel fine?

Advanced liver fibrosis is often silent until cirrhosis complications develop. A high NFS (>0.676) with no symptoms still warrants prompt hepatology evaluation, FibroScan, and metabolic workup. Do not delay care because you feel well—early specialist management slows progression and enables surveillance for hepatocellular carcinoma if cirrhosis is confirmed.

NAFLD Fibrosis Score (NFS) Calculator

Calculate the NAFLD Fibrosis Score from age, BMI, diabetes/IFG status, AST, ALT, platelet count, and albumin. Screen for advanced liver fibrosis (F3–F4) in NAFLD/MASLD with validated cutoffs and exportable results.

Enter your details — results appear below after you calculate.

Demographics & body metrics

Age (years)

Height (cm)

Weight (kg)

BMI is calculated automatically from height and weight for the NFS formula

Diabetes or impaired fasting glucose (IFG)?

Select Yes for type 2 diabetes, prediabetes, or IFG (fasting glucose 100–125 mg/dL) — adds 1.13 NFS points per the Angulo formula

Liver function & blood tests

AST (U/L)

Typical reference: 10–40 U/L

ALT (U/L)

Typical reference: 7–56 U/L · must be > 0 for ratio

Platelet units

Albumin units

Platelet count (×10⁹/L)

Typical reference: 150–400 ×10⁹/L

Albumin (g/dL)

Typical reference: 3.5–5.5 g/dL (35–55 g/L)

How this NAFLD Fibrosis Score (NFS) calculator works

This tool computes the NAFLD Fibrosis Score (NFS)—a validated blood-based index for advanced liver fibrosis (F3–F4) in NAFLD/MASLD per Angulo et al. Hepatology 2007. NFS < −1.455 rules out advanced fibrosis (~93% NPV); NFS > 0.676 rules it in (~90% PPV); scores between are indeterminate and need FibroScan or specialist review.

Enter age, height and weight (BMI is calculated automatically), diabetes/IFG status, AST and ALT (U/L), platelet count (×10⁹/L or ×10³/µL), and albumin (g/dL or g/L) from your latest blood work.

Results include NFS value, full formula component breakdown, fibrosis category (rule out / indeterminate / rule in), AST/ALT ratio analysis, individual lab reference status, health score, clinical interpretation, FibroScan referral guidance, and PDF export. NFS is for patients with known or suspected fatty liver—not general population screening.

Pair with our Fatty Liver Risk, Metabolic Syndrome Risk, Diabetes Risk, and Insulin Resistance calculators for broader metabolic liver context. This is an educational screening tool—not a diagnosis. Seek hepatology care for high or indeterminate NFS. Emergency care for jaundice, vomiting blood, or severe abdominal swelling.

Quick reference: NFS < −1.455 rules out advanced fibrosis · −1.455 to 0.676 is indeterminate (needs FibroScan) · NFS > 0.676 suggests F3–F4 fibrosis. Scroll below for formula breakdown, worked examples, NFS vs FIB-4, FibroScan cutoffs, clinical screening guidance, diet and treatment options, common mistakes, and FAQs. Compare with our FIB-4 Liver Fibrosis Calculator when NFS is indeterminate.

NAFLD Fibrosis Score (NFS) Calculator – Advanced Liver Fibrosis Screening

Millions search "NAFLD fibrosis score", "NFS calculator", and "liver fibrosis blood test" each year. The NAFLD Fibrosis Score (NFS) is a validated formula that estimates the probability of advanced fibrosis—bridging fibrosis (F3) or cirrhosis (F4)—in non-alcoholic fatty liver disease (NAFLD/MASLD) using routine blood tests: age, BMI, diabetes/IFG, AST, ALT, platelets, and albumin. No biopsy required for initial screening. Our free calculator applies the Angulo et al. Hepatology 2007 formula with published cutoffs, component breakdown, clinical interpretation, and exportable results.

Pair results with our Fatty Liver Risk Calculator, Metabolic Syndrome Risk Calculator, Diabetes Risk Calculator, and Insulin Resistance Calculator for comprehensive metabolic liver health assessment.

Why Calculate the NAFLD Fibrosis Score?

NAFLD/MASLD affects roughly 25–30% of adults worldwide and can progress silently from simple fat accumulation to inflammation (NASH/MASH) and fibrosis. Advanced fibrosis increases risk of cirrhosis, liver failure, and hepatocellular carcinoma. NFS helps triage who needs urgent hepatology referral versus who can continue lifestyle management—with ~93% negative predictive value at the low cutoff and ~90% positive predictive value at the high cutoff in validation studies.

1What You Enter

Demographics & metabolic

Age — years (18–100)
BMI — calculated from height and weight
Diabetes/IFG — type 2 diabetes, prediabetes, or impaired fasting glucose

Laboratory values

AST & ALT — U/L from liver panel
Platelet count — ×10⁹/L or ×10³/µL
Albumin — g/dL or g/L

Example (Rule out — low fibrosis risk)

Age 42, BMI 28, no diabetes, AST 32, ALT 45, platelets 250, albumin 4.3 g/dL → AST/ALT 0.71 → NFS ≈ −2.87 — below −1.455, advanced fibrosis unlikely. Continue lifestyle optimization.

Example (Rule in — high fibrosis risk)

Age 62, BMI 35, diabetes yes, AST 78, ALT 52, platelets 145, albumin 3.4 g/dL → AST/ALT 1.50 → NFS ≈ 2.40 — above 0.676, high probability of advanced fibrosis. Hepatology referral advised.

2NFS Formula & Cutoffs

NFS = −1.675 + 0.037×age + 0.094×BMI + 1.13×(diabetes/IFG) + 0.99×(AST/ALT) − 0.013×platelets(×10⁹/L) − 0.66×albumin(g/dL)

NFS range	Interpretation	Action
< −1.455	Low probability of advanced fibrosis	Lifestyle care; routine monitoring
−1.455 to 0.676	Indeterminate	FibroScan / hepatology referral
> 0.676	High probability of advanced fibrosis	Urgent specialist evaluation

3Understanding NAFLD Fibrosis Stages

Stage	Description	NFS relevance
F0	No fibrosis; steatosis only	Usually NFS < −1.455
F1	Mild perisinusoidal fibrosis	Often low NFS; reversible with weight loss
F2	Moderate fibrosis	May be indeterminate NFS
F3	Bridging fibrosis	Often NFS > 0.676
F4	Cirrhosis	High NFS; specialist surveillance required

NFS vs Other Fibrosis Tests

Test	Inputs	Best use
NFS (this calculator)	Age, BMI, diabetes, AST, ALT, platelets, albumin	NAFLD-specific; rule out/in advanced fibrosis
FIB-4	Age, AST, ALT, platelets	General liver fibrosis screening; no BMI/albumin
FibroScan	Ultrasound elastography (kPa)	Gold-standard non-invasive staging when NFS indeterminate
Liver biopsy	Histology	Definitive diagnosis when non-invasive tests discordant

Treatment & Lifestyle When NFS Is Elevated

7–10% weight loss — most effective intervention for early MASLD; reduces liver fat and fibrosis progression
Mediterranean diet — limits fructose, refined carbs, and saturated fat; emphasizes olive oil, fish, vegetables
150+ min/week exercise — aerobic activity reduces hepatic steatosis independent of weight loss
Glycemic control — optimize HbA1c in diabetes; GLP-1 agonists show fibrosis benefits in trials
Avoid alcohol — even moderate intake worsens NAFLD
Specialist therapies — resmetirom for F2–F3 MASH; hepatology-guided only

4How NFS Is Calculated — Step by Step

Full formula

NFS = −1.675 + 0.037×age + 0.094×BMI + 1.13×(diabetes/IFG) + 0.99×(AST/ALT) − 0.013×platelets − 0.66×albumin

Platelets in ×10⁹/L (same numeric value as ×10³/µL). Albumin in g/dL. Diabetes/IFG = 1 if yes, 0 if no. BMI is computed from height (cm) and weight (kg): BMI = weight ÷ height(m)².

What each variable contributes

Variable	Coefficient	Effect on NFS
Age (per year)	+0.037	Older age raises NFS slightly
BMI (per kg/m²)	+0.094	Higher BMI raises NFS
Diabetes / IFG	+1.13	Adds fixed 1.13 points if present
AST/ALT ratio	+0.99 × ratio	Ratio ≥1.0 strongly raises NFS
Platelets (×10⁹/L)	−0.013 × count	Lower platelets lower NFS mathematically
Albumin (g/dL)	−0.66 × level	Lower albumin raises NFS substantially

Example (Indeterminate zone)

Age 55, height 168 cm, weight 90 kg (BMI 31.9), no diabetes, AST 50, ALT 40, platelets 200, albumin 4.0 g/dL → AST/ALT 1.25 → NFS ≈ −0.63 — indeterminate (−1.455 to 0.676). Cannot rule out or confirm advanced fibrosis; request FibroScan and hepatology review.

NFS Risk Categories — Rule Out, Indeterminate & Rule In

Category	NFS cutoff	NPV / PPV	Typical fibrosis stage	Recommended action
Rule out	< −1.455	NPV ~93%	F0–F2 (no/mild/moderate fibrosis)	Lifestyle care; annual LFTs
Indeterminate	−1.455 to 0.676	Cannot exclude F3–F4	F1–F3 possible (~32% of patients)	FibroScan; hepatology referral
Rule in	> 0.676	PPV ~90%	F3–F4 (bridging fibrosis/cirrhosis)	Urgent specialist evaluation

Sensitivity ~90% and specificity ~60% at the low cutoff; sensitivity ~67% and specificity ~97% at the high cutoff in the original Angulo cohort. NFS performs best at the extremes—indeterminate scores need elastography.

Understanding NAFLD, MASLD & NASH — Disease Progression

NAFLD (non-alcoholic fatty liver disease) is now often termed MASLD (metabolic dysfunction-associated steatotic liver disease), emphasising insulin resistance and metabolic syndrome as root causes. Simple steatosis is fat accumulation without significant inflammation—often reversible. NASH/MASH (steatohepatitis) adds inflammation and hepatocyte injury. Untreated, NASH can progress through fibrosis stages to cirrhosis and hepatocellular carcinoma. NFS specifically screens for advanced fibrosis (F3–F4) in patients who already have fatty liver—not for diagnosing steatosis itself.

Stage	What happens	Reversible?	NFS role
Steatosis (F0)	Fat in liver cells; enzymes may be normal	Yes — lifestyle change	Usually NFS < −1.455
NASH/MASH inflammation	Fat + inflammation; ALT/AST often elevated	Often — with 7–10% weight loss	Variable NFS
Fibrosis F1–F2	Early scar tissue in liver	Partially reversible	Low or indeterminate NFS
Bridging fibrosis (F3)	Extensive scarring between portal areas	Limited — specialist care	Often NFS > 0.676
Cirrhosis (F4)	End-stage scarring; impaired liver function	Not reversible — prevent progression	High NFS; HCC surveillance needed

Understanding Each NFS Lab Variable

AST & ALT

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are liver enzymes released when hepatocytes are injured. In simple steatosis, ALT often exceeds AST. As fibrosis advances, mitochondrial AST rises and the AST/ALT ratio ≥ 1.0 becomes a fibrosis signal—adding up to ~1.0 NFS points per unit of ratio.

Typical AST: 10–40 U/L
Typical ALT: 7–56 U/L (men), 7–35 (women)
Muscle injury and alcohol also raise AST

Platelet count

Platelets (thrombocytes) are produced in bone marrow and cleared by the spleen. In advanced liver disease, portal hypertension causes splenic sequestration and low platelets. NFS subtracts 0.013 points per ×10⁹/L—so thrombocytopenia mathematically lowers NFS, but may itself indicate serious liver disease.

Normal: 150–400 ×10⁹/L
<150 ×10⁹/L: thrombocytopenia — evaluate for fibrosis
Enter as ×10⁹/L or ×10³/µL (same number)

Serum albumin

Albumin is the main protein synthesised by the liver. Low albumin reflects reduced synthetic function in advanced fibrosis or cirrhosis. Each 1 g/dL below normal subtracts 0.66 NFS points (increases score). Dehydration and nephrotic syndrome also lower albumin—interpret with clinical context.

Normal: 3.5–5.5 g/dL (35–55 g/L)
<3.5 g/dL: hypoalbuminemia — liver or nutritional cause

Age, BMI & diabetes

Older age and higher BMI independently associate with fibrosis progression in NAFLD cohorts. Type 2 diabetes and impaired fasting glucose (100–125 mg/dL) add a fixed +1.13 NFS points because insulin resistance accelerates hepatic scarring. Up to 70% of type 2 diabetics have coexisting fatty liver.

South Asians: overweight BMI ≥23 kg/m² (WHO Asia-Pacific)
Pair with our HbA1c Calculator

NFS vs FIB-4 — Which Fibrosis Score to Use?

Feature	NFS (this calculator)	FIB-4
Formula	Age, BMI, diabetes, AST/ALT, platelets, albumin	(Age × AST) ÷ (Platelets × √ALT)
Validated for	NAFLD/MASLD specifically	General liver fibrosis (HBV, HCV, NAFLD)
Low cutoff	< −1.455 (rule out F3–F4)	< 1.3 (rule out advanced fibrosis)
High cutoff	> 0.676 (rule in F3–F4)	> 2.67 (rule in advanced fibrosis)
Best practice	Use NFS first in NAFLD; if indeterminate, add FIB-4 and FibroScan for concordant staging

FibroScan & When NFS Is Indeterminate

Transient elastography (FibroScan) measures liver stiffness in kilopascals (kPa) using ultrasound shear wave—non-invasive and widely available in India (₹3,000–8,000 at most centres). When NFS falls in the indeterminate zone (−1.455 to 0.676), FibroScan is the recommended next step per AASLD and EASL guidelines.

FibroScan (kPa)	Fibrosis stage	Clinical meaning
< 7.0	F0–F1	No/significant fibrosis unlikely
7.0–9.5	F2	Significant fibrosis possible
9.5–12.5	F3	Advanced fibrosis — specialist care
> 12.5	F4 (cirrhosis)	Cirrhosis likely — surveillance for HCC, varices

Symptoms — When Fatty Liver Becomes Serious

Early / often silent

No symptoms in 70–80% of NAFLD cases
Mild fatigue or low energy
Vague right upper abdominal discomfort
Elevated ALT/AST on routine health check-up
Fatty liver found incidentally on ultrasound

Advanced / urgent signs

Unexplained weight loss
Yellow eyes or skin (jaundice)
Abdominal swelling (ascites)
Dark urine, pale stools, easy bruising
Confusion (hepatic encephalopathy) — emergency

High or indeterminate NFS with any advanced symptom warrants same-day medical evaluation—not watchful waiting.

NAFLD Fibrosis Screening in India

Prevalence: NAFLD/MASLD affects ~25–30% of Indian adults—higher in urban, sedentary populations
Diabetes overlap: ~77 million Indians with diabetes; up to 70% may have coexisting fatty liver
Lower BMI risk: South Asians develop significant hepatic steatosis at BMI ≥23 (Asian overweight cutoff)
Lean NAFLD: 10–20% of cases occur at normal BMI with high waist or poor diet quality
Test costs: LFT panel ₹500–1,500; CBC ₹200–500; FibroScan ₹3,000–8,000 at major diagnostic centres
Silent progression: Most advanced fibrosis is caught on corporate health panels, not from symptoms—NFS helps triage who needs FibroScan
Diet drivers: Refined carbs, fried snacks, sugary beverages, and sedentary desk jobs accelerate fibrosis in Indian adults

Recommended Lab Panel for NFS Calculation

Gather these from a single fasting or non-fasting blood draw (NFS itself does not require fasting). Ask your doctor for a comprehensive metabolic liver workup:

Liver function tests (LFTs): AST, ALT, GGT, bilirubin, alkaline phosphatase, albumin, total protein
Complete blood count (CBC): platelet count (required for NFS)
Fasting glucose & HbA1c: confirms diabetes/IFG status for NFS
Lipid profile: triglycerides and HDL often elevated in MASLD
Abdominal ultrasound: confirms hepatic steatosis if not already done
FibroScan: if NFS is indeterminate or high

Pair with our Triglyceride/HDL Ratio Calculator, Cholesterol Risk Calculator, and BUN/Creatinine Ratio Calculator for broader metabolic and kidney assessment.

Diet & Weight Loss to Improve NFS Over Time

Sustained lifestyle change is the only proven intervention that reverses early fibrosis. Clinical trials show 7–10% body weight loss reduces liver fat, normalises enzymes, and can shift NFS toward lower values over 6–12 months.

Mediterranean pattern: olive oil, fish, legumes, vegetables, whole grains
Cut fructose: soft drinks, packaged juices, excess sweet chai, mithai
Limit fried food: samosas, pakoras, restaurant deep-fried items
Increase fibre: dal, vegetables, millets (jowar, bajra)

150+ min/week aerobic exercise: brisk walking, cycling, swimming
Resistance training: 2×/week preserves muscle during weight loss
Zero alcohol during active fibrosis management
Recheck NFS 6–12 months after sustained lifestyle change

Medications & Conditions That Affect NFS Inputs

May raise AST/ALT

Statins (usually mild, often continue safely)
Methotrexate, amiodarone, isoniazid
Paracetamol overdose
Strenuous exercise before blood draw
Non-alcoholic and alcoholic hepatitis flares

May lower platelets / albumin

Portal hypertension (advanced fibrosis)
Malnutrition, chronic illness
Nephrotic syndrome (low albumin)
Chemotherapy (bone marrow suppression)
Autoimmune thrombocytopenia (unrelated to liver)

Always interpret NFS with your medication list and symptom timeline. Repeat abnormal labs after resolving acute illness before staging decisions.

MASH Treatment Options When Fibrosis Is Confirmed

Resmetirom (Rezdiffra): FDA-approved for MASH with F2–F3 fibrosis; hepatology-prescribed only
GLP-1 agonists: semaglutide, tirzepatide — weight loss plus emerging fibrosis benefits in trials
Pioglitazone: evidence in selected nondiabetic and diabetic NASH patients (specialist decision)
Vitamin E: non-diabetic NASH with biopsy-proven steatohepatitis (declining first-line use)
Bariatric surgery: considered for BMI ≥35 with failed lifestyle intervention and significant fibrosis

Never start or stop liver medications based solely on calculator results. All pharmacotherapy requires hepatologist guidance after proper staging.

Common Mistakes When Using the NFS

1. Using NFS without confirmed fatty liver

NFS is validated in NAFLD/MASLD patients—not for screening the general population. Confirm steatosis on ultrasound or MRI first, or use our Fatty Liver Risk Calculator for initial screening.

2. Ignoring indeterminate scores

~32% of patients fall in the indeterminate zone. Do not assume mild disease—request FibroScan or hepatology referral rather than repeating NFS alone.

3. Dividing AST by ALT incorrectly

Use the same blood draw for both enzymes. ALT must be > 0. If ALT is very low, the ratio becomes unreliable—repeat labs when clinically stable.

4. Applying NFS in heavy alcohol use

NFS was validated in non-alcoholic fatty liver. Heavy alcohol (>14 units/week) invalidates interpretation—evaluate for alcoholic liver disease overlap with our Alcohol Impact Calculator.

5. Treating low NFS as a "healthy liver" guarantee

Low NFS excludes advanced fibrosis but not steatosis, inflammation, or early F1–F2 fibrosis. Continue lifestyle optimisation and periodic enzyme monitoring.

When to Seek Emergency Care

Jaundice (yellow eyes or skin) with high NFS
Vomiting blood or black tarry stools
Severe abdominal pain or rapidly enlarging abdomen
Confusion, drowsiness, or personality change (hepatic encephalopathy)
Call 102 or 108 (India ambulance) or go to the nearest emergency department

Frequently Asked Questions (FAQs)

Related Calculators

You might also be interested in these related health and wellness calculators:

Fatty Liver Risk Calculator

Assess NAFLD/MASLD fatty liver risk from BMI, waist, diabetes, diet, alcohol and lifestyle. Get weight-loss targets, diet tips, exercise guidance, and liver test recommendations.

Try Calculator →

FIB-4 Liver Fibrosis Calculator

Calculate the FIB-4 index from age, AST, ALT and platelet count. Screen for advanced liver fibrosis (F3–F4) in NAFLD, viral hepatitis and chronic liver disease with validated cutoffs and PDF export.

Try Calculator →

Fatty Liver Severity Calculator

Calculate the Hepatic Steatosis Index (HSI) from ALT, AST, BMI, sex and diabetes status. Screen for fatty liver steatosis severity in NAFLD/MASLD with validated cutoffs and PDF export.

Try Calculator →

Metabolic Syndrome Risk Calculator

Screen metabolic syndrome with all 5 harmonized criteria—waist, triglycerides, HDL, blood pressure and fasting glucose. Asian waist cutoffs, diet tips, exercise guidance and lab recommendations.

Try Calculator →

Insulin Resistance (HOMA-IR) Calculator

Calculate HOMA-IR from fasting glucose and fasting insulin to estimate insulin resistance. Get category, HOMA-β, and educational guidance for metabolic health.

Try Calculator →

HbA1c ↔ Average Blood Glucose Calculator

Convert HbA1c (%) to estimated average glucose (eAG) and back using the ADAG formula. ADA category bands, mg/dL and mmol/L units, PDF export.

Try Calculator →

Type 2 Diabetes Risk Assessment Calculator

Assess type 2 diabetes risk using the Indian Diabetes Risk Score (IDRS). Enter age, waist, family history, activity, and clinical history. Low to Very High risk with PDF export.

Try Calculator →

Triglyceride/HDL Ratio Calculator

Calculate triglyceride/HDL ratio from fasting lipids for cardiometabolic risk, insulin resistance screening, AHA lipid interpretation, and PDF export.

Try Calculator →

Calculator Categories

Explore more free tools by health topic. Your calculator's category is highlighted below.

This calculator